Ignite Creation Date:
2024-05-05 @ 4:52 PM
Last Modification Date:
2024-10-26 @ 9:25 AM
Study NCT ID:
NCT00336479
Status:
COMPLETED
Last Update Posted:
2014-07-23
First Post:
2006-06-09
Brief Title:
Phase 2 Study of VX-950 Pegasys and Copegus in Hepatitis C
Sponsor:
Vertex Pharmaceuticals Incorporated
Organization:
Vertex Pharmaceuticals Incorporated
Study Overview
Official Title:
A Phase 2 Study of VX-950 in Combination With Peginterferon Alfa-2a Pegasys With Ribavirin Copegus in Subjects With Genotype 1 Hepatitis C Who Have Not Received Prior Treatment
Status:
COMPLETED
Status Verified Date:
2014-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Study the effectiveness of telaprevir VX-950 in combination with Pegylated Interferon Alfa 2a Peg-IFN-alfa-2a and Ribavirin RBV in reducing plasma hepatitis C virus HCV ribonucleic acid RNA levels
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None